In light of heightened attention to insulin and the Trump Administration’s new Part D model to address out-of-pocket costs for insulin for Medicare beneficiaries, we analyzed out-of-pocket spending on insulin by beneficiaries enrolled in Part D drug plans, variation in Part D plan formulary coverage and tier placement of insulin products, and trends in prices for insulin.
- view as grid
- view as list
This brief answer key questions on affordability of COVID-19 testing and treatment for people who are uninsured and those insured through private coverage, Medicare, and Medicaid.
This 10-question quiz tests your knowledge about the coronavirus and COVID-19, including issues around symptoms, testing, number of cases and deaths, and cost sharing for treatment.
These FAQs provide the latest guidance on testing and treatment related to COVID-19 for Medicare beneficiaries.
Annual Updates on Eligibility Rules, Enrollment and Renewal Procedures, and Cost-Sharing Practices in Medicaid and CHIP
Since 2000, the Kaiser Family Foundation’s Program on Medicaid and the Uninsured has issued regular updates examining changes and trends in the eligibility rules, enrollment and renewal procedures and cost-sharing practices in Medicaid and CHIP. Those reports are compiled here.
As the coronavirus continues to spread, the number of people on Medicare admitted to the hospital for COVID-19 related illness is expected to rise. We analyze how much Medicare beneficiaries could pay out-of-pocket for an inpatient hospital admission under traditional Medicare (assuming no supplemental coverage) or Medicare Advantage plans.
Drew Altman looks at the numbers for COVID-19 treatment, and why it may soon be necessary for Congress to waive out-of-pocket costs for treatment.
This data note captures February 2020 poll findings on the public’s worries about and experiences with unexpected and surprise medical bills.
When it comes to family budget concerns, unexpected medical bills top Americans’ list of worries, with two-thirds (65%) of the public saying they are at least somewhat worried, including 35% who say they are “very” worried, the latest KFF Health Tracking Poll finds. Fewer Americans say they are at least…
In this post for The JAMA Forum, Larry Levitt examines both the Democratic candidates’ proposals and the Trump administration’s record on lowering drug prices, which remains a top issue for the public with bi-partisan support.